Keros Therapeutics Reports Q3 Earnings Beat with Significant Revenue Growth
Keros Therapeutics (NASDAQ: KROS) reported third-quarter financial results that significantly exceeded market expectations. The company posted a GAAP earnings per share (EPS) of $0.70, surpassing estimates by $1.72, and reported revenue of $40 million, which represents an 181.7% increase year-over-year. The substantial revenue beat of $26.11 million highlights rapid scaling for the company. Following a recent $20 million milestone achievement, Keros Therapeutics has also initiated a $5 million share buyback program, signaling management's confidence in its current financial position and capital allocation strategy.
Tickers: $KROS
Topics: earnings report milestone payment revenue growth share buyback